Landmark Study Suggests Skipping Sentinel Lymph Node Biopsy for Many Breast Cancer Patients
A major clinical trial indicates that sentinel lymph node biopsy (SLNB) can be safely avoided in carefully selected women with early-stage breast cancer, potentially reducing unnecessary stress, complications, and healthcare costs. The findings, stemming from a large-scale study conducted across the Netherlands, represent a significant step toward more personalized and less invasive cancer care.
The standard procedure for assessing potential metastases in breast cancer has long been the SLNB, but it isn’t without drawbacks. Patients can experience pain, sensory disturbances, and, in some cases, lymphedema following the procedure. Furthermore, the results of the biopsy often have limited impact on subsequent treatment decisions for many women.
Rethinking the Standard of Care
“Our study shows that we can safely skip this operation in carefully selected patients,” stated the principal investigator of the trial. “The oncological results remain the same, while you avoid a stressful procedure with possible complications.” The research, conducted in 25 Dutch hospitals, involved 1,733 women diagnosed with early breast cancer who were randomly assigned to either undergo SLNB or forgo the procedure.
After a five-year follow-up period, researchers found that regional recurrences – the return of cancer in the lymph nodes – were exceedingly rare in both groups. The rate of recurrence was 0.5% among women who underwent SLNB, compared to 1.2% in those who did not. This difference, researchers emphasized, was minimal and fell comfortably within pre-defined safety margins.
Who Benefits Most?
The study’s results are particularly relevant for women aged 50 and older with hormone receptor-positive, HER2-negative tumors measuring up to approximately 2 centimeters. “This group makes up the majority of our breast cancer patients in this study,” the principal investigator explained. “For them, this is an important step towards less invasive, more customized care.”
Omitting SLNB offers a range of benefits beyond patient comfort. Shorter surgical times, fewer post-operative complications, and reduced healthcare expenditures are all potential advantages. However, the principal investigator stressed the continued importance of careful patient selection and diligent follow-up care.
Funding and Future Implications
The BOOG 2013-08 study was funded by KWF Kankerbestrijding, Zilveren Kruis and ZonMw, underscoring the collaborative effort behind this important research. These findings have the potential to reshape treatment protocols and improve the quality of life for countless women facing a breast cancer diagnosis.
